Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Esketamine Market Growth Performance Trended Historically, And What Lies Ahead?#_x000D_

In recent times, the esketamine market has experienced significant growth. The market is projected to increase from $1.37 billion in 2024 to $1.51 billion in 2025, with a compound annual growth rate (CAGR) of 9.9%. Several factors contribute to this growth during the historic period, including a surge in patient numbers, escalating global mental health issues, improved disease awareness levels, a rising demand for new therapeutic treatments, and positive regulatory authorizations._x000D_

_x000D_

Anticipations are high for the esketamine market as it is projected to witness substantial growth in the coming years. By 2029, it is estimated to reach a value of $2.26 billion, expanding at a compound annual growth rate (CAGR) of 10.7%. This growth through the forecast period is due to several factors such as the rising incidence of treatment-resistant depression, surge in funding for research and developmental activities, increasing demand for intelligent healthcare infrastructure, growing uptake of telehealth services, and more acceptance of esketamine as a viable treatment measure. The forecast period is also expected to see certain trends like collaborations between biotech companies and mental health agencies, the use of robotics in healthcare, application of personalized medicine approaches, deployment of sensor-based devices, and feasibility of combination treatments._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp_x000D_

_x000D_

#Which Factors and External Forces Are Driving Demand in the Esketamine Market?#_x000D_

The surge in the occurrence of treatment-resistant depression (TRD) is projected to drive the expansion of the esketamine market in future years. TRD is described as depression, unaffected after the implementation of at least two varied antidepressant medications at rightful doses for an adequate time span. The growth in TRD cases can be attributed to the insufficient efficacy of conventional antidepressants, contributing to extensive and repetitive depressive instances. Esketamine aids TRD by supplying a rapid-acting process that focuses on the NMDA receptors, giving respite for patients unresponsive to standard antidepressants. For example, the National Institute of Mental Health (NIMH), a federal agency in the U.S., in September 2023, disclosed that around 30% of people having major depressive disorder in the U.S. are unresponsive to standard treatments in 2023. Hence, the escalating prevalence of treatment-resistant depression is fuelling the development of the esketamine market._x000D_

_x000D_

#Which Segments in the Esketamine Offer the Most Growth?#_x000D_

The esketamine market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types_x000D_

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders_x000D_

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients_x000D_

4) By Application: General Anesthetic, Treatment-Resistant Depression_x000D_

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets _x000D_

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection_x000D_

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray_x000D_

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Esketamine Market?# Market?#_x000D_

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Cutting-Edge Market Trends Are Expected to Drive theEsketamine Market’s Growth?#_x000D_

Significant market players in the esketamine sector are focusing their efforts on creating superior treatment options such as monotherapy in order to offer an improvement over what is achieved with placebos in managing depression symptoms. Monotherapy involves the use of just one drug or treatment in controlling a disease or medical condition rather than incorporating several therapies. A prime example was seen in January 2025, when US-based pharmaceutical firm, Johnson & Johnson, revealed that SPRAVATO (esketamine), had received approval from the US Food and Drug Administration (FDA) as the sole monotherapy for adults suffering from treatment-resistant depression (TRD). Backed by clinical trials, the approval showed SPRAVATO’s swift calming effect on depressive symptoms, with notable improvement seen within the first 24 hours. This development presents a crucial option for an approximate 30% of people not affected by conventional antidepressants, thus eliminating the requirement for simultaneous oral medication. Although SPRAVATO has an acceptable safety record, it is given under a Risk Evaluation and Mitigation Strategy (REMS) to handle potential side effects. This achievement represents a substantial progression in managing TRD, providing fresh prospects for enhanced patient recovery outcomes._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Esketamine Market?#_x000D_

Esketamine refers to a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is used for treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model